AMNOG 2.0 – significant changes for the industry since January 2023, correct – Dr. Flume?

Klicken Sie auf den unteren Button, um den Inhalt von zu laden.

Inhalt laden

Join us in the latest episode where pharmacist and head of a regional physicians association, Matthias Flume, engages in a thought-provoking discussion with host Stefan Walzer, exploring the intricate tapestry of reforms enveloped within the AMNOG (Arzneimittelmarktneuordnungsgesetz) 2.0, especially scrutinizing those unveiled in 2023!

🚀 Dive Deep into the Core of Pharmaceutical Reforms!

Matthias unearths various pivotal changes, including the mandated discounts for products with no additional benefit rating and the perceptible adjustments in the orphan drug area, dissecting the threshold reduction for annual sales in the full regular benefit assessment. 🚀

🌎 Explore the Global Impact!

Navigate through their insightful discussion on how these reforms potentially sculpt Germany’s presence on the global stage, especially in the orphan drugs market, and assess Germany’s unique positioning in evaluating them! 🌎

💡 Illuminating the Opaqueness of Drug Pricing!

Embark on a journey through the complexities and pragmatic implications of drug pricing, dissecting the nuances of arbitration boards, pricing mechanisms, and the often intricate physician prescription behaviors amidst the recent reforms. 💡

🤔 Facing the Challenges Head-On!

Explore the potential disconnect between pricing strategies and actual prescription practices, as our experts shed light on the vital need for enhancing transparency and communication with physicians regarding pricing negotiations and adjustments. 🤔

👥 Join Matthias and Stefan as they scrutinize the germane issues of drug pricing, contemplate future adjustments within the system, and ponder upon the possible shifts influenced by the upcoming national elections and continual changes within the healthcare landscape! 👥

🎧 Tune in to immerse yourself in a conversation that not only explores the multidimensional aspects of the healthcare and pharmaceutical reimbursement system but also poses potent questions regarding its future amidst regulatory and structural shifts! 🎧

A journey through the dynamics of pharmaceutical pricing and reforms awaits you, amplifying both economic and patient care perspectives amidst the shifting tides of the healthcare system in Germany! Don’t miss it! 🚀🚀